The startup provides biotechnology products and research services for 3D cell, tissue, and organoid culture, utilizing pharmaceutical-grade materials that maintain the bioactivity of natural extracellular matrices. This enables animal-free drug discovery and development, offering a more ethical approach to pharmaceutical research while ensuring mechanical tunability and reproducibility.
Funding
$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Conventional 2D cell cultures lack the complex cell-matrix interactions and mechanical cues present in native tissues, leading to inaccurate results in drug discovery, disease modeling, and tissue engineering. Animal-derived extracellular matrices (ECMs) like Matrigel introduce batch-to-batch variability and ethical concerns, hindering reproducibility and translational relevance.
Solution
Gelomics provides LunaGel™, a suite of advanced 3D cell culture technologies that enable the creation of highly controlled and reproducible 3D tissue models. LunaGel™ is a photocrosslinkable, animal-free ECM that allows researchers to fine-tune matrix stiffness and mimic the mechanical properties of healthy and diseased tissues. The technology facilitates the formation of functional microtissues and spheroids in minutes, offering a physiologically relevant environment for cell growth, differentiation, and interaction. Gelomics' solutions support a wide range of applications, including drug discovery, personalized medicine, disease modeling, tissue engineering, and 3D bioprinting, providing more predictive and ethical alternatives to traditional 2D cultures and animal-derived matrices.
Target Audience
Gelomics serves researchers in academia, pharmaceutical companies, and contract research organizations (CROs) seeking advanced 3D cell culture solutions for drug discovery, disease modeling, and regenerative medicine.
Features
- Photocrosslinking technology for rapid gelation and user-defined control over matrix stiffness
- Biologically active ECMs containing cell-instructive motifs and attachment sites
- Universal compatibility with numerous cell types, broadening experimental possibilities
- Responsive degradability, allowing for cellular remodeling and adaptation to dynamic culture conditions
- Reliable consistency, ensuring reproducible results from batch to batch
- Suitable for various applications, including tunable matrices, angiogenesis studies, drug response analysis, tissue engineering, 3D bioprinting, and in vivo models